Skip to main content

Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 18, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Dec. 18, 2024 -- A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric Blood & Cancer.

Sameera Ramjan, from Memorial Sloan Kettering Cancer Center in New York City, and colleagues offered patients enrolled in the Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents participation in an optional neurocognitive study assessing longitudinal changes in neurocognitive function. The analysis included 3- and 4-year-old patients enrolled in the study.

The researchers found that 3-year-old patients did not differ from 4-year-olds in terms of their ability to perform or complete the brief Cogstate battery assessing psychomotor function (detection) and attention (identification). These findings persisted at four time-point assessments, through 52 weeks after diagnosis.

"This report demonstrates that computerized testing, such as Cogstate, can be successfully administered to 3-year-old patients who are undergoing treatment for acute lymphoblastic leukemia, thereby capturing serial test data on a vulnerable patient population that, in prior studies, have demonstrated worse neurocognitive deficits," the authors write. "Consequently, changing future study inclusion criteria to include patients diagnosed at the age of 3 years will ultimately serve to improve our understanding of at-risk patients and the neurocognitive trajectory of this age group both during treatment as well as into survivorship, thereby leading to the development of early interventions."

One author disclosed ties to the pharmaceutical industry; two authors disclosed ties to Cogstate.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections

WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...

Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia

WEDNESDAY, April 30, 2025 -- For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless...

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.